Abbott Laboratories (NYSE:ABT) Releases Quarterly Earnings Results, Meets Estimates

Abbott Laboratories (NYSE:ABT) released its quarterly earnings results on Wednesday. The healthcare product maker reported $1.34 EPS for the quarter, hitting the consensus estimate of $1.34, Zacks reports. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. Abbott Laboratories updated its FY 2025 guidance to 5.050-5.250 EPS and its Q1 2025 guidance to 1.050-1.090 EPS.

Abbott Laboratories Trading Up 2.9 %

Shares of NYSE:ABT opened at $116.78 on Wednesday. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $121.64. The firm has a fifty day moving average price of $114.87 and a 200 day moving average price of $112.95. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $202.55 billion, a PE ratio of 35.50, a P/E/G ratio of 2.43 and a beta of 0.73.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $0.59 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 annualized dividend and a dividend yield of 2.02%. Abbott Laboratories’s dividend payout ratio is 71.73%.

Wall Street Analyst Weigh In

ABT has been the topic of a number of recent analyst reports. Oppenheimer initiated coverage on Abbott Laboratories in a report on Tuesday, October 8th. They set an “outperform” rating and a $130.00 price target on the stock. Jefferies Financial Group raised their target price on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company a “hold” rating in a research note on Thursday, October 17th. Barclays upped their price target on shares of Abbott Laboratories from $143.00 to $149.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI raised their price objective on shares of Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research note on Thursday, January 2nd. Finally, UBS Group upped their target price on Abbott Laboratories from $143.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $131.93.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.